SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data at Epilepsy Pipeline Conference

Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody™ Therapeutics Against Multiple Immuno-Oncology Targets

Third Rock Ventures and The Column Group Launch Nurix with $25.1 Million Financing to Target Key Regulatory Pathway

Agios Pharmaceuticals Reports First Quarter 2014 Financial Results

Foundation Medicine Announces 2014 First Quarter Results and Recent Highlights

Eleven Biotherapeutics to Report First Quarter 2014 Financial Results on May 15, 2014

Eleven Biotherapeutics Presents Data on Novel Protein Therapeutics for Treatment of Front and Back of Eye Diseases at ARVO 2014 Annual Meeting

Foundation Medicine to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference

Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis

Rhythm Presents Positive GI Motility Results for Relamorelin (RM-131) in Phase 2 Chronic Constipation Study

SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Office

Eleven Biotherapeutics Appoints Gary Sternberg, M.D., M.B.A., as Executive Vice President Corporate and Business Development

SAGE Therapeutics Receives U.S. Orphan Drug Designation for Lead Compound SAGE-547 to Treat Status Epilepticus

Agios Pharmaceuticals to Webcast Conference Call of First Quarter 2014 Financial Results on May 8, 2014

Allena Pharmaceuticals Announces Positive Phase 1 Data of ALLN-177 for the Treatment of Kidney Stones

New Preclinical Data Demonstrate Kala Pharmaceuticals’ Topical LE-MPPÂ Provides Equal or Better Drug Exposure Compared to Lotemax®

New Clinical Data using the NvisionVLE™ Imaging System to be presented at Digestive Disease Week® 2014

Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers

Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency

Alcresta Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Develop Point-of-Care Nutritional Products

Foundation Medicine Announces Timing for First Quarter 2014 Financial Results and Conference Call

PanOptica Raises $45 Million to Finance Clinical Development of Anti-VEGF Eye Drop for Wet AMD

Blueprint Medicines Presents Positive Data on First Selective FGFR4 Inhibitor

Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

Foundation Medicine and Clovis Oncology Expand Collaboration to Develop Novel Companion Diagnostic for Rucaparib in Ovarian Cancer

Constellation Pharmaceuticals will give a presentation on EZH2 and exhibit posters on EZH2 and BET at the AACR Annual Meeting, April 5-9 in San Diego, CA.

Foundation Medicine Announces New Data Highlighting FoundationOneâ„¢ and FoundationOneâ„¢ Heme to be Presented at the AACR Annual Meeting 2014

Eleven Biotherapeutics Added to Russell Indexes on March 31, 2014

SAGE Therapeutics Appoints Howard H. Pien to the Company’s Board of Directors

SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus